NCT05756062View on ClinicalTrials.gov

Supplementation With a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients With Keratoconus

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Keratoconus
Interventions
DIETARY_SUPPLEMENT

Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)

Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months

Trial Locations (1)

46015

FISABIO Medical Ophthalmology (FOM), Valencia

All Listed Sponsors
lead

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

OTHER

NCT05756062 - Supplementation With a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients With Keratoconus | Biotech Hunter | Biotech Hunter